• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

2-year data backs DarioHealth digital diabetes platform

August 24, 2023 By Sean Whooley

DarioHealthDarioHealth (Nasdaq:DRIO) today announced new research demonstrating sustainably improved outcomes with its digital diabetes platform.

New York-based DarioHealth designed its digital health solutions to combine a clinically intelligent platform with consumer insights. It helps to drive sustainable behavior change to improve the management of chronic conditions, including diabetes.

The research, presented at the ADCES23 Annual Conference, produced positive results for the platform over a two-year period.

Results demonstrated 29% user engagement improvements over two years. Users with high-risk diabetes demonstrated reductions in high blood glucose reading ratios and monthly average glucose. These reductions correlated with increased engagement.

Yifat Hershcovitz, VP of clinical and scientific affairs at DarioHealth, said the solutions drive healthier behaviors and outcomes. This research provides evidence that the company’s approach to outcome-based engagement provides a long-term benefit, Hershcovitz said. The company’s members and benefits now see sustainable health improvements, according to the VP.

“Every facet of our solution is designed with one goal in mind: sustainably improving health outcomes,” Chief Medical Officer Dr. Omar Manejwala said. “This new research, like many of our studies, helps extend our understanding – and the market’s understanding – of what Dario digital health solutions are doing to achieve that goal and deliver the results our partners have come to expect.”

Filed Under: Clinical Trials, Diabetes, Technology Tagged With: dariohealth

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS